Skip to content

Study on cognitive impairment of psychiatric disorders based on multi-type biomarkers and functional near-infrared spectroscopy

Study on cognitive impairment of psychiatric disorders based on multi-type biomarkers and functional near-infrared spectroscopy

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2400090643
Enrollment
Unknown
Registered
2024-10-10
Start date
2023-09-14
Completion date
Unknown
Last updated
2024-10-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Mental disorder

Interventions

Health Control Group:No interventions, not applicable.
Schizophrenia Group:No interventions, not applicable.
Mood Disorder Group:No interventions, not applicable.

Sponsors

Renmin Hospital of Wuhan University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
16 Years to 45 Years

Inclusion criteria

Inclusion criteria: 1. Willing to sign an informed consent form; 2. Commit to comply with the research procedures and cooperate with the implementation of the entire study; 3. Age between 16-45 years old; 4. For the schizophrenia group or mood disorder group, they should meet the diagnostic criteria for schizophrenia or mood disorders in the "Diagnostic and Statistical Manual of Mental Disorders (DSM-5)"; for the healthy control group, they should be evaluated by at least two attending psychiatrists and have no history of any psychiatric illness or family history. 5. If it is a woman of childbearing age, she should use contraception for at least one month before screening and commit to using contraception throughout the entire study and continue until the specified time after the study ends.

Exclusion criteria

Exclusion criteria: 1. Subjects who have taken vitamins, nonsteroidal anti-inflammatory drugs, or corticosteroids that may affect prostaglandin metabolism in the past two weeks; 2. Patients with chronic sleep disorders; 3. History of alcohol or drug abuse or dependence on psychotropic substances; 4. Pregnant or lactating women; 5. Meet the diagnostic criteria for intellectual disability in the DSM-V; 6. Patients with organic brain diseases or other unstable or severe physical diseases.

Design outcomes

Primary

MeasureTime frame
Oxygenated hemoglobin concentration;Deoxyhemoglobin concentration;Transient receptor potential vanilloid type 1 channel, TRPV1;sirtuin-3, SIRT3;Positive and Negative Syndrome Scale, PANSS;Hamilton Anxiety Scale, HAMA;Brief Assessment of Cognition in Schizophrenia, BACS;Montgomery-Asberg Depression Rating Scale, MADRS;

Secondary

MeasureTime frame
Superoxide Dismutase 2, SOD2;Inflammatory factor;Bech-Rafaelsen Mania Rating Scale,BRMS;Eye Basic Emotion Discrimination Task, EBEDT;Faux pas recognition;

Countries

China

Contacts

Public ContactHuiling Wang

Renmin Hospital of Wuhan University

hlwang@whu.edu.cn+86 138 8602 9165

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026